LEP and relapsing-remitting multiple sclerosis: Importantly, combining in vivo dimethyl fumarate treatment with in vitro mTOR inhibition, also through leptin neutralization, reactivated NRF2, reinstated SLC7A11 expression, and rescued the proliferative potential of Treg cells from RRMS patients.